UNITY BIOTECHNOLOGY, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.49 USD | +1.36% |
|
-2.61% | -22.80% |
Presenter SpeechRoss Weinreb (Analysts)Great. Good afternoon, everybody. My name is Ross Weine...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.
Calendar
2024-06-21
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.47
USD
Average target price
6
USD
Spread / Average Target
+308.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.80% | 24.68M | |
| +9.02% | 114B | |
| +11.42% | 104B | |
| -12.38% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -2.72% | 17.89B | |
| +8.07% | 14.28B | |
| +35.06% | 12.55B |
- Stock Market
- Equities
- UBX Stock
- News Unity Biotechnology, Inc.
- Transcript : Unity Biotechnology, Inc. Presents at Goldman Sachs 41st Annual Global Healthcare Conference, Jun-11-2020 01